Steno2tech - Continuous Glucose Monitoring and Type 2 Diabetes.

The prevalence of type 2 diabetes is increasing. Although medical treatment options have increased, still less than a third obtain their optimal glycemic goal. The use of continuous glucose monitoring (CGM) in persons with type 1 diabetes has shown to be the most important driver for improvement in glycemic control-even more than insulin-pump therapy-but the use of technology in type 2 diabetes are not yet reimbursed and has been investigated in very few studies.

The study will be a single center, prospective, randomized, open-labelled, three-armed study with the randomization 2:1:2 in group A with CGM, group B with CGM and peer-support, group C as a control group with SMBG. The study will run for 12 months and will include 100 adult participants with insulin-treated type 2 diabetes, treated at the outpatient clinic at Steno Diabetes Center Copenhagen. Recruitment will begin in August 2020 and end in May 2022. Final 12-month follow-up is anticipated to be in July 2023.

The study is investor-initiated. The primary investigator (Nanna Lind, PhD. Student) will be responsible for execution of this study under guidance by the sponsor Kirsten Nørgaard. Results will be published in international peer-reviewed journals.

Our study will provide evidence of the effectiveness of the use of CGM in the treatment for type 2 diabetes, potentially shaping clinical guidelines for SMBG frequency and timing as well as use of technology in type 2 diabetes with an impact on both healthcare and healthcare costs.

Inclusion criteria

• Type 2 diabetes according to clinical definitions
• Treated with insulin injections at least once daily on top of diet and exercise recommendations. Insulin therapy has been used for at least 12 months. Can be additionally treated with one or more different oral antidiabetic drugs (except sulfonylurea), and/or glucagon-like-peptide 1 (GLP-1) analogues
• Attending the outpatient clinic at Steno Diabetes Center Copenhagen for at least 12 months
• Age ≥ 18 years
• HbA1c > 58 mmol/mol (7.5%) at two consecutively measurements over at least 3 months
• Willing to use possible interventions; to perform self-monitoring of blood glucose (SMBG) as requested by the investigators AND to use CGM continuously without calibration for a 12-month period.
• Willing to intensify non-medical and medical treatment to achieve better glucose control.

Exclusion criteria

• Inability to understand the patient information and give informed consent
• Not speaking and understanding Danish
• Treatment with sulfonylurea (SU) during the last 3 months before study start
• New antidiabetic treatment the last three months
• Use of systematic corticosteroids
• Visual impairment
• Severe skin allergy for adhesive tape to the patch of CGM or other skin condition that inhibits the use of a CGM device
• Comorbidity which does not allow lowering of HbA1c to 53 mmol/mol (7.0%)
• Hypoglycemic unawareness
• Impaired renal disease with eGFR < 45 ml/min/1.73m2
• Conditions that impact the stability of a HbA1c measurement (chronic liver disease, haemoglobinopathy, anemia etc.)
• Known or suspected alcohol or drug abuse
• Already using Flash glucose monitoring (Libre) or CGM
• Enrolled in another clinical study
• Pregnancy, intend to become pregnant, breastfeeding or not using adequate contraceptive methods